At the news
? BULLISHIMPACT 6/10 PRESS-RELEASE filed Jul 6, 2026 at 06:50 ET
Pharvaris announced FDA acceptance of its New Drug Application (NDA) for deucrictibant immediate-release capsules for on-demand treatment of hereditary angioedema (HAE) attacks, with a PDUFA target action date of April 23, 2027. The NDA includes positive Phase 3 data (RAPIDe-3) showing rapid symptom relief and a well-tolerated safety profile. This milestone reduces regulatory uncertainty and positions deucrictibant as a potential first oral therapy for acute HAE attacks, though approval is still pending.
- FDA accepted NDA for deucrictibant IR (20 mg) for on-demand treatment of HAE attacks
- PDUFA target action date set for April 23, 2027
- Phase 3 RAPIDe-3 study met primary and all 11 secondary endpoints with statistical significance
- Median time to onset of symptom relief: 1.28 hours; median time to complete resolution: 11.95 hours
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access